FDA Accepts Axsome's NDA for Narcolepsy Drug AXS-12, Sets May 2027 Decision Date
AXSM has more than doubled off its 52-week low of $96.09.
Summary
The FDA accepted Axsome's NDA for AXS-12 (reboxetine) to treat cataplexy in narcolepsy, with a PDUFA date of May 1, 2027. No advisory committee is planned, which often signals a straightforward review. This is a new pipeline catalyst for a drug with Orphan Drug Designation, targeting an estimated 70% of narcolepsy patients who experience cataplexy. The acceptance follows Axsome's recent regulatory wins, including the April 2026 approval of AUVELITY for Alzheimer's agitation and the June 2026 Sunosi patent settlement. AXS-12 could become the first FDA-approved treatment specifically for cataplexy, expanding Axsome's CNS franchise. The May 2027 decision is a key long-term value driver, though the timeline means near-term revenue impact is limited.
At the time of this announcement, AXSM was trading at $229.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $12.1B. The 52-week trading range was $96.09 to $260.19. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.